Skip to main content
Evidence Snapshot

Histamine H2 receptor

CHEMBL2882 SINGLE PROTEIN Cavia porcellus
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:30:15Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2882
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Histamine H2 receptor as ChEMBL target CHEMBL2882, mapped to UniProt P47747. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Histamine H2 receptor
SINGLE PROTEIN · Cavia porcellus
As of 2026-09-13
ChEMBL target ID
CHEMBL2882
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P47747
Histamine H2 receptor
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Histamine H2 receptor matters

As of 2026-09-13

Histamine H2 receptor is reviewed as Histamine H2 receptor (UniProt P47747); the current evidence base includes 18 approved drugs, 995 compounds, and 240 assays, with lead potency reaching pChEMBL 9.6.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 18 approved drugs, 995 compounds, and 240 assays for this target. The dominant activity type is EC50. CHEMBL2165630 is the current potency anchor at pChEMBL 9.6.

Use CHEMBL2165630 as the tractability anchor when discussing potency (pChEMBL 9.6).

Activity source · ChEMBL 36 via Core Engine
18 approved pChEMBL 9.6
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Histamine H2 receptor matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P47747, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

995
Total Compounds
240
Total Assays
18
Approved Drugs
IC50: 26.0, KI: 58.0, EC50: 161.0, KD: 151.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL2165630
 9.6 EC50 —
No preferred name
CHEMBL2165632
 9.4 EC50 —
No preferred name
CHEMBL2165628
 9.3 EC50 —
No preferred name
CHEMBL2165642
 9.2 EC50 —
No preferred name
CHEMBL72193
 9.2 Ki —

Approved Drugs

Structure Compound First Approval
HISTAMINE DIHYDROCHLORIDE
CHEMBL1533310
 2008
CLOMIPRAMINE
CHEMBL415
 1989
FAMOTIDINE
CHEMBL902
 1986
RANITIDINE
CHEMBL1790041
 1983
CIMETIDINE
CHEMBL30
 1977
AMITRIPTYLINE
CHEMBL629
 1961
HISTAMINE
CHEMBL90
 1939
MIANSERIN
CHEMBL6437
 —
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:30:15Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2882